Legal6 Aug 2025, 08:41 pm
Glenmark Pharmaceuticals to Pay $37.75 Million to Settle Antitrust Lawsuits in the US
AI Summary
Glenmark Pharmaceuticals Ltd. has disclosed that its subsidiary, Glenmark Pharmaceuticals Inc., USA, is named in multiple antitrust and consumer protection lawsuits in the Eastern District of Pennsylvania, US. The lawsuits allege price-fixing, market allocation, and related anticompetitive conduct in the generic drugs market. Glenmark USA has agreed to settle with the putative direct purchaser class for $37.75 million, payable in two instalments. The settlement does not admit any liability or illegality.
Key Highlights
- Glenmark Pharmaceuticals Inc., USA is involved in antitrust and consumer protection lawsuits in the US
- The lawsuits allege price-fixing, market allocation, and related anticompetitive conduct in the generic drugs market
- Glenmark USA has agreed to pay $37.75 million to settle the dispute with the direct purchaser class
- The settlement is subject to court approval and payable in two instalments
- The settlement does not admit any liability or illegality